J.P. Morgan Says Salesforce's AI Worries Are Overblown, Slaps a $250 Price Target on the Stock
On August 13, 2026, J.P. Morgan analyst Samik Chatterjee started covering Salesforce (ticker: CRM) with an Overweight rating and a December 2027 price target of $250 per share, according to Yahoo Finance. The stock had previously been Not Rated by the firm, so this is a fresh call rather than a small upgrade. Chatterjee's central argument: the market's anxiety about Salesforce's ability to compete in artificial intelligence is, in his words, "overblown."
An Overweight rating means J.P. Morgan expects Salesforce to outperform similar stocks the firm covers, on a risk-adjusted basis, over the investment horizon. The $250 price target is a separate, absolute number — it says the stock should reach that specific price by December 2027. Together, the rating and the target say two things at once: CRM should beat its peers, and it should hit a specific price by a specific date.
The competitive question hanging over Salesforce is whether its AI products — chiefly Agentforce and the broader Data Cloud ecosystem — can generate meaningful new revenue, or whether AI-native startups and the big cloud providers (the so-called hyperscalers: Microsoft, Amazon, Google) will commoditize the layer where Salesforce has historically made its money. Skeptics point to longer sales cycles for AI-powered products, the risk that new AI offerings eat into existing license revenue (cannibalization), and the possibility that large corporate customers test the waters with pilots rather than signing big contracts.
Chatterjee's call pushes back on that framing directly. The practical read on "overblown" is that the market has discounted Salesforce's AI revenue potential too heavily relative to what the company's existing customer base and distribution advantage can deliver. Salesforce is not starting from scratch in AI. It is layering AI capabilities on top of a CRM (customer relationship management) platform with deep enterprise penetration, and the bull case rests on selling AI features into accounts that already pay for Sales Cloud, Service Cloud, and Marketing Cloud. When the procurement relationship, the data integrations, and the user licenses already exist, the friction of getting customers to spend more on AI is lower.
The December 2027 target carries its own risks worth noting. A roughly 15-month horizon gives the thesis plenty of runway to play out, but it also insulates the call from near-term earnings results. If Salesforce's fiscal 2027 and 2028 results disappoint on AI revenue contribution, a long-dated target can be revised downward without ever having been proven wrong in a testable way. Investors should treat the December 2027 date as a feature that reduces accountability pressure, not as a sign of high conviction in a specific near-term turning point.
The broader context here is the valuation gap between Salesforce and the AI infrastructure names — the hyperscalers and semiconductor companies — that have captured most of investor enthusiasm. CRM has traded at a discount to its own historical software valuation multiples and at a steep discount to those AI infrastructure stocks. A bullish initiation from a top-tier bank does not close that gap on its own, but it does put a credible sell-side stamp on the argument that the discount is excessive.
For portfolio managers running enterprise software exposure, the actionable question is whether Chatterjee's thesis lines up with their own research on Agentforce pipeline metrics, Data Cloud attach rates, and the competitive pressure from Microsoft Copilot and other tools in the CRM-adjacent AI layer. The note provides a framework and a price anchor; it does not substitute for that work.
For individual investors, the headline is simpler. A major Wall Street firm with a deep software franchise just told clients that Salesforce's AI story is better than the market thinks, and put a $250 price tag on that conviction. Whether that conviction is rewarded depends on execution over the next 15 months — and on whether the concerns Chatterjee calls "overblown" turn out to be premature rather than wrong.
